Use of modified Clostridium perfringens enterotoxin fragments for claudin targeting in liver and skin cells
Claudins regulate paracellular permeability in different tissues. The claudin-binding domain of Clostridium perfringens enterotoxin (cCPE) is a known modulator of a claudin subset. However, it does not efficiently bind to claudin-1 (Cldn1). Cldn1 is a pharmacological target since it is (i) an essent...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
MDPI
2019
|
| _version_ | 1797071701693956096 |
|---|---|
| author | Beier, L Rossa, J Woodhouse, S Bergmann, S Kramer, H Protze, J Eichner, M Piontek, A Vidal-Y-Sy, S Brandner, J Krause, G Zitzmann, N Piontek, J |
| author_facet | Beier, L Rossa, J Woodhouse, S Bergmann, S Kramer, H Protze, J Eichner, M Piontek, A Vidal-Y-Sy, S Brandner, J Krause, G Zitzmann, N Piontek, J |
| author_sort | Beier, L |
| collection | OXFORD |
| description | Claudins regulate paracellular permeability in different tissues. The claudin-binding domain of Clostridium perfringens enterotoxin (cCPE) is a known modulator of a claudin subset. However, it does not efficiently bind to claudin-1 (Cldn1). Cldn1 is a pharmacological target since it is (i) an essential co-receptor for hepatitis C virus (HCV) infections and (ii) a key element of the epidermal barrier limiting drug delivery. In this study, we investigated the potential of a Cldn1-binding cCPE mutant (i) to inhibit HCV entry into hepatocytes and (ii) to open the epidermal barrier. Inhibition of HCV infection by blocking of Cldn1 with cCPE variants was analyzed in the Huh7.5 hepatoma cell line. A model of reconstructed human epidermis was used to investigate modulation of the epidermal barrier by cCPE variants. In contrast to cCPEwt, the Cldn1-binding cCPE-S305P/S307R/S313H inhibited infection of Huh7.5 cells with HCV in a dose-dependent manner. In addition, TJ modulation by cCPE variant-mediated targeting of Cldn1 and Cldn4 opened the epidermal barrier in reconstructed human epidermis. cCPE variants are potent claudin modulators. They can be applied for mechanistic in vitro studies and might also be used as biologics for therapeutic claudin targeting including HCV treatment (host-targeting antivirals) and improvement of drug delivery. |
| first_indexed | 2024-03-06T22:57:10Z |
| format | Journal article |
| id | oxford-uuid:60cb7d3d-6c31-4b89-ab98-32f26a99c73f |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T22:57:10Z |
| publishDate | 2019 |
| publisher | MDPI |
| record_format | dspace |
| spelling | oxford-uuid:60cb7d3d-6c31-4b89-ab98-32f26a99c73f2022-03-26T17:55:47ZUse of modified Clostridium perfringens enterotoxin fragments for claudin targeting in liver and skin cellsJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:60cb7d3d-6c31-4b89-ab98-32f26a99c73fEnglishSymplectic Elements at OxfordMDPI2019Beier, LRossa, JWoodhouse, SBergmann, SKramer, HProtze, JEichner, MPiontek, AVidal-Y-Sy, SBrandner, JKrause, GZitzmann, NPiontek, JClaudins regulate paracellular permeability in different tissues. The claudin-binding domain of Clostridium perfringens enterotoxin (cCPE) is a known modulator of a claudin subset. However, it does not efficiently bind to claudin-1 (Cldn1). Cldn1 is a pharmacological target since it is (i) an essential co-receptor for hepatitis C virus (HCV) infections and (ii) a key element of the epidermal barrier limiting drug delivery. In this study, we investigated the potential of a Cldn1-binding cCPE mutant (i) to inhibit HCV entry into hepatocytes and (ii) to open the epidermal barrier. Inhibition of HCV infection by blocking of Cldn1 with cCPE variants was analyzed in the Huh7.5 hepatoma cell line. A model of reconstructed human epidermis was used to investigate modulation of the epidermal barrier by cCPE variants. In contrast to cCPEwt, the Cldn1-binding cCPE-S305P/S307R/S313H inhibited infection of Huh7.5 cells with HCV in a dose-dependent manner. In addition, TJ modulation by cCPE variant-mediated targeting of Cldn1 and Cldn4 opened the epidermal barrier in reconstructed human epidermis. cCPE variants are potent claudin modulators. They can be applied for mechanistic in vitro studies and might also be used as biologics for therapeutic claudin targeting including HCV treatment (host-targeting antivirals) and improvement of drug delivery. |
| spellingShingle | Beier, L Rossa, J Woodhouse, S Bergmann, S Kramer, H Protze, J Eichner, M Piontek, A Vidal-Y-Sy, S Brandner, J Krause, G Zitzmann, N Piontek, J Use of modified Clostridium perfringens enterotoxin fragments for claudin targeting in liver and skin cells |
| title | Use of modified Clostridium perfringens enterotoxin fragments for claudin targeting in liver and skin cells |
| title_full | Use of modified Clostridium perfringens enterotoxin fragments for claudin targeting in liver and skin cells |
| title_fullStr | Use of modified Clostridium perfringens enterotoxin fragments for claudin targeting in liver and skin cells |
| title_full_unstemmed | Use of modified Clostridium perfringens enterotoxin fragments for claudin targeting in liver and skin cells |
| title_short | Use of modified Clostridium perfringens enterotoxin fragments for claudin targeting in liver and skin cells |
| title_sort | use of modified clostridium perfringens enterotoxin fragments for claudin targeting in liver and skin cells |
| work_keys_str_mv | AT beierl useofmodifiedclostridiumperfringensenterotoxinfragmentsforclaudintargetinginliverandskincells AT rossaj useofmodifiedclostridiumperfringensenterotoxinfragmentsforclaudintargetinginliverandskincells AT woodhouses useofmodifiedclostridiumperfringensenterotoxinfragmentsforclaudintargetinginliverandskincells AT bergmanns useofmodifiedclostridiumperfringensenterotoxinfragmentsforclaudintargetinginliverandskincells AT kramerh useofmodifiedclostridiumperfringensenterotoxinfragmentsforclaudintargetinginliverandskincells AT protzej useofmodifiedclostridiumperfringensenterotoxinfragmentsforclaudintargetinginliverandskincells AT eichnerm useofmodifiedclostridiumperfringensenterotoxinfragmentsforclaudintargetinginliverandskincells AT pionteka useofmodifiedclostridiumperfringensenterotoxinfragmentsforclaudintargetinginliverandskincells AT vidalysys useofmodifiedclostridiumperfringensenterotoxinfragmentsforclaudintargetinginliverandskincells AT brandnerj useofmodifiedclostridiumperfringensenterotoxinfragmentsforclaudintargetinginliverandskincells AT krauseg useofmodifiedclostridiumperfringensenterotoxinfragmentsforclaudintargetinginliverandskincells AT zitzmannn useofmodifiedclostridiumperfringensenterotoxinfragmentsforclaudintargetinginliverandskincells AT piontekj useofmodifiedclostridiumperfringensenterotoxinfragmentsforclaudintargetinginliverandskincells |